Dr. Erin Boh says understanding disease pathophysiology provides treatment option insights for immune mediated inflammatory diseases that do not have FDA-approved therapies.
According to dermatologist Erin E. Boh, MD, PhD, understanding disease pathophysiology is key to treating immune mediated inflammatory diseases (IMIDs) that do not have efficacious, FDA-approved therapies.
In her presentation, “Off Label Use of Biologics,” at at the Winter Clinical Dermatology Conference 2021, she drew a parallel between the cytokines elevated in psoriasis with those in lichen planus and granuloma annulare to illustrate how to expand the treatment armamentarium for these or other uncommon diseases that do not currently have good treatment options.
Using IMIDs lichen planus and granuloma annulare as examples, Dr. Boh walks through the disease pathology to arrive at off-label biologic treatment options.
Dr. Boh is Chair, Joseph Chastain Clinical Professor of Dermatology, Department of Dermatology, Tulane University School of Medicine, New Orleans, La.
